Prostate Cancer Clinical Trial

Celgene CC-5013-PC-002

INDICATION:
Castrate-resistant Prostate Cancer

TITLE:
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-resistant Prostate cancer

IRB NAME:
Western IRB

STATUS:
Open for enrollment

PHASE:
3

PURPOSE:
To compare the overall survival benefit of docetaxel and prednisone with and without lenalidomide as first-line therapy in chemotherapy-naïve metastatic castrate-resistant prostate cancer patients

ELIGIBILITY:
Candidates must:

• Be aged 18 years or older
• Be willing to complete an electronic diary and pain assessments without assistance or with minimal assistance from trained site personnel and/or a caregiver
• Have histologically confirmed adenocarcinoma of the prostate and have documented disease progression while receiving or following hormonal therapy for treatment of advanced prostate cancer despite castrate levels of serum testosterone resulting from orchiectomy or luteinizing hormone-releasing agonist

DURATION:
Screening, weekly visits on cycles 1 and 2; 1 visit on cycle 3 and beyond until disease progression.

CONTACT/ADDITIONAL INFO:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630